151751-Najiba-Chargi

352 CHAPTER 17 14. Watters AL, Cope S, Keller MN, Padilla M, Enciso R. Prevalence of trismus in pa - tients with head and neck cancer: A sys- tematic review with meta-analysis. Head Neck . 2019;41(9):3408-3421. doi:10.1002/ hed.25836 15. Kraaijenga SA, Hamming-Vrieze O, Verhei - jen S, et al. Radiation dose to the masseter and medial pterygoid muscle in relation to trismus after chemoradiotherapy for advanced head and neck cancer. Head Neck . 2019;41(5):1387-1394. doi:10.1002/ hed.25573 16. van der Geer SJ, van Rijn P V., Kamstra JI, et al. Prevalence and prediction of trismus in patients with head and neck cancer: A cross-sectional study. Head Neck . 2019;41(1):64-71. doi:10.1002/hed.25369 17. Van den Steen L, Van Gestel D, Vanderveken O, et al. Evolution of self ‐ perceived swallow- ing function, tongue strength and swallow ‐ related quality of life during radiotherapy in head and neck cancer patients. Head Neck . 2019;41(7):2197-2207. doi:10.1002/ hed.25684 18. BalmAJM, Rasch CRN, Schornagel JH, et al. High-dose superselective intra-arterial cis - platin and concomitant radiation (radplat) for advanced head and neck cancer. Head Neck . 2004;26(6):485-493. doi:10.1002/ hed.20006 19. Ackerstaff AH, Balm AJM, Rasch CRN, et al. First-year quality of life assessment of an intraarterial (radplat) versus intravenous chemoradiation phase III trial. Head Neck . 2009;31(1):77-84. doi:10.1002/hed.20937 20. Karsten RT, Al-Mamgani A, Bril SI, et al. Sarcopenia, a strong determinant for pro- longed feeding tube dependency after chemoradiotherapy for head and neck cancer. Head Neck . 2019;41(11):4000-4008. doi:10.1002/hed.25938 21. Clayburgh D, Olson B, Edwards J, et al. Association of Sarcopenia with Oncologic Outcomes of Primary Surgery or Definitive Radiotherapy among Patients with Local- ized Oropharyngeal Squamous Cell Carci - noma. JAMA Otolaryngol - Head Neck Surg . 2020;146(8):714-722. doi:10.1001/jamao - to.2020.1154 22. Passchier E, Stuiver MM, van der Molen L, Kerkhof SIC, van den Brekel MWM, Hilgers FJM. Feasibility and impact of a dedicated multidisciplinary rehabilitation programon health-related quality of life in advanced head and neck cancer patients. Eur Arch Oto-Rhino-Laryngology . 2016;273(6):1577- 1587. doi:10.1007/s00405-015-3648-z 23. Van Der Molen L, Van RossumMA, Burkhead LM, Smeele LE, Rasch CRN, Hilgers FJM. A randomized preventive rehabilitation trial in advanced head and neck cancer patients treated with chemoradiotherapy: Feasibil - ity, compliance, and short-term effects. Dysphagia . 2011;26(2):155-170. doi:10.1007/ s00455-010-9288-y 24. Swartz JE, Pothen AJ, Wegner I, et al. Feasibility of using head and neck CT im - aging to assess skeletal muscle mass in head and neck cancer patients. Oral Oncol . 2016;62:28-33. doi:10.1016/j.oraloncolo - gy.2016.09.006 25. Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol . 2017;71:26-33. doi:10.1016/j.oraloncology.2017.05.012 26. Crary MA, Carnaby Mann GD, Groher ME. Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients. Arch Phys Med Reha- bil . 2005;86(8):1516-1520. doi:10.1016/j. apmr.2004.11.049